Soyeon-Park-14650.jpg

Soyeon Park

PhD Student in Entrepreneurship and Family Enterprise
Email [email protected]
Find out More about the Author
CASE STUDY

Roche and Fuzeon (T-20): Balancing Scientific Rigor, Patient Access, and Scarcity in HIV Treatment (A)

By  Henrich Greve,  Soyeon Park
Add to Cart new

Roche faced a dilemma because it had developed the first drug that could treat patients with multidrug-resistant HIV and, as a result, could prolong the lives of HIV patients whose illness had progressed the most significantly.

    Published 12 Aug 2026

    Reference 7172

    Topic Leadership & Organisations

    Industry Pharmaceuticals

    Region Europe

    View

    Roche and Fuzeon (T-20): Balancing Scientific Rigor, Patient Access, and Scarcity in HIV Treatment (A)

    Add to Cart new

    Roche faced a dilemma because it had developed the first drug that could treat patients with multidrug-resistant HIV and, as a result, could prolong the lives of HIV patients whose illness had progressed the most significantly.

      View
      CASE STUDY

      Roche and Fuzeon (T-20): Managing Access After Approval (B)

      By  Henrich Greve,  Soyeon Park
      Add to Cart new

      Roche faced a dilemma because it had developed the first drug that could treat patients with multidrug-resistant HIV and, as a result, could prolong the lives of HIV patients whose illness had progressed the most significantly.

        Published 12 Aug 2026

        Reference 7172

        Topic Leadership & Organisations

        Industry Pharmaceuticals

        Region Europe

        View

        Roche and Fuzeon (T-20): Managing Access After Approval (B)

        Add to Cart new

        Roche faced a dilemma because it had developed the first drug that could treat patients with multidrug-resistant HIV and, as a result, could prolong the lives of HIV patients whose illness had progressed the most significantly.

          View